

MEDICIS PHARMACEUTICAL CORP
Form 8-K
July 23, 2012

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

July 17, 2012

Date of Report (Date of earliest event reported)

Medicis Pharmaceutical Corporation

(Exact name of registrant as specified in its charter)

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 8-K

(State of Incorporation)

(Commission File Number)

(IRS Employer Identification Number)

7720 North Dobson Road

Scottsdale, Arizona 85256

(Address of principal executive offices) (Zip Code)

(602) 808-8800

(Registrant's telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

U.S. Patent and Trademark Office Issues New Patent Covering ZYCLARA® (Imiquimod) Cream, 2.5%, and an Issue Notification and Notice of Allowance for Two New Patents Covering ZYCLARA (Imiquimod) Cream, 3.75%

On July 17, 2012, the U.S. Patent and Trademark Office (the "USPTO") issued to Medicis Pharmaceutical Corporation (the "Company") U.S. Patent No. 8,222,270 (U.S. Application No. 13/179,315), entitled "2 x 2 x 2 Week Treatment Regimen for Treating Actinic Keratosis with Pharmaceutical Compositions Formulated with 2.5% Imiquimod (the "270 Patent"). The 270 Patent, which expires in 2029, covers a method of daily administration of ZYCLARA® (Imiquimod) Cream, 2.5%, which consists of treating the full face or balding scalp of a patient with actinic keratosis with ZYCLARA for two weeks, followed by a two-week non-treatment period, followed by a second two-week treatment period. The Company anticipates that it will launch ZYCLARA Cream, 2.5% in the third quarter of 2012.

On July 18, 2012, the USPTO issued an Issue Notification for U.S. Patent No. 8,236,816 (U.S. Application No. 13/181,499), entitled "2 x 2 x 2 Week Dosing Regimen for Treating Actinic Keratosis with Pharmaceutical Compositions Formulated with 3.75% Imiquimod (the "816 Patent"). The 816 Patent, which will expire in 2029, is scheduled to issue on August 7, 2012. The 816 Patent will cover a method of daily administration of ZYCLARA (Imiquimod) Cream, 3.75%, which consists of treating the full face or balding scalp of a patient with actinic keratosis with ZYCLARA for two weeks, followed by a two-week non-treatment period, followed by a second two-week treatment period. The USPTO had previously issued a Notice of Allowance for the patent application for the 816 Patent on May 24, 2012, as well as a Notice of Allowance for an additional patent that covers a novel method of daily administration of ZYCLARA Cream, 3.75%, U.S. Application No. 13/182,433, entitled "Method of Treating Actinic Keratosis with 3.75% Imiquimod Cream (the "433 Patent Application"), on May 25, 2012. The Company expects that the USPTO will issue the patent underlying the 433 Patent Application during the third quarter of 2012. The Company launched ZYCLARA Cream, 3.75% in March 2012.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements included that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements, including those related to the timing with respect to the issuance of patents for the Company's United States patent applications directed to the use of ZYCLARA Cream, 3.75% for the treatment of actinic keratosis, and those related to the anticipated launch of ZYCLARA Cream, 2.5%, are based on certain assumptions made by the Company based on its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. No assurances can be given, however, that these activities, events or developments will occur or that such results will be achieved. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company. Several of these risks are outlined in the Company's most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 and the Annual Report on Form 10-K for the year ended December 31, 2011, and other documents we file with the Securities and Exchange Commission. Forward-looking statements represent the judgment of Company management as of the date of this Current Report on Form 8-K, and the Company disclaims any intent or obligation to update any forward-looking statements contained herein, which speak as of the date hereof. Among other things, there can be no assurance that the issuance of the Issuance Notification and the Notice of Allowance by the USPTO relating to the patents covering ZYCLARA Cream, 3.75% will result in the final issuance of such patents, as well as no assurance as to the timing of the final issuance of such patents, and there can be no assurance as to the launch of ZYCLARA Cream, 2.5% or the timing of such launch.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDICIS PHARMACEUTICAL CORPORATION

Date: July 23, 2012

By: /s/ Seth L. Rodner
Seth L. Rodner
Executive Vice President, Chief Legal Officer and
Corporate Secretary